Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as standard therapies for advanced nonsmall cell lung cancer (NSCLC) patients with EGFR mutation positive. Because these targeted therapies could cause tumor necrosis and shrinkage, the purpose of the study is to sear...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiaobo, Zhang, Yang, Ma, Yuxiang, Zhou, Ting, Zhang, Jianwei, Hong, Shaodong, Sheng, Jin, Zhang, Zhonghan, Yang, Yunpeng, Huang, Yan, Zhang, Li, Zhao, Hongyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979775/
https://www.ncbi.nlm.nih.gov/pubmed/27495021
http://dx.doi.org/10.1097/MD.0000000000004176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979775/
https://www.ncbi.nlm.nih.gov/pubmed/27495021
http://dx.doi.org/10.1097/MD.0000000000004176

Ejemplares similares